Design, Physicochemical Evaluation and In Vitro Dissolution Studies of Transdermal Patches Containing Aceclofenac

IRFAN NEWAZ KHAN\textsuperscript{A}, MARZINA AJRIN\textsuperscript{A}, MD. RAZIBUL HABIB\textsuperscript{B}, MARIA ISLAM KHAN\textsuperscript{A}, MD. MOMINUR RAHMAN\textsuperscript{B}, MOHAMMAD SHOHEL\textsuperscript{C}

\textsuperscript{A} Department of Pharmacy, University of Science & Technology Chittagong (USTC), Bangladesh, \textsuperscript{B} Department of Pharmacy, East West University, Dhaka, Bangladesh, \textsuperscript{C} International Islamic University Chittagong, Bangladesh, \textsuperscript{D} Department of Pharmacy, North South University, Dhaka, Bangladesh.

Abstract

The present study was designed to develop a suitable matrix type transdermal drug delivery system (TDDS) of Aceclofenac using blends of three different polymeric combinations of Polyvinyl pyrrolidine (PVP) and ethylcellulose (EC). Physical studies including moisture content, moisture uptake, flatness to study the stability of the formulations and in vitro dissolution of the experimental formulations were performed. It was observed that as the concentration of the hydrophilic polymer, PVP, increased in the formulation, the rate of dissolution increased subsequently and the best result found for the polymer ratio 3:5. From the study of release mechanism it was found that the higuchi plot showed reasonably straight line with high correlation coefficient. It was also found that there were no significant reactions developed during the contact of patch with the dermis. Hence, it can be reasonably concluded that Aceclofenac can be formulated into the transdermal matrix type patches to sustain its release characteristics and the polymeric composition (PVP/EC, 3:5) was found to be the best choice for manufacturing transdermal patches of Aceclofenac among the formulations studied.

Key words:

Aceclofenac, Transdermal Patch, PVP, Ethylcellulose

How to Cite this Paper:


Copyright © 2010 IJDDR, Irfan Newaj Khan et al. This is an open access paper distributed under the copyright agreement with Serials Publication, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article History:------------------------

Date of Submission: 02-05-2011
Date of Acceptance: 12-07-2011
Conflict of Interest: NIL
Source of Support: NONE

Introduction

Transdermal drug delivery is the delivery of drug across epidermis to achieve systemic effects. The
success of transdermal patches lies in their commercialization. Transdermal patches control the delivery of drugs at controlled rates by employing an appropriate combination of hydrophilic and lipophilic polymer [1-4]. The main components of transdermal patches are liner, drug, adhesive, membrane and backing. There are four main types of transdermal patches are listed below:

2. Multi-layer Drug-in-Adhesive
3. Drug Reservoir-in-Adhesive
4. Drug Matrix-in-Adhesive

At present, the most common form of delivery of drugs is the oral route. While this has the notable advantage of easy administration, it also has significant drawbacks - namely poor bioavailability due to hepatic metabolism (first pass) and the tendency to produce rapid blood level spikes (both high and low), leading to a need for high and frequent dosing, which can be both cost prohibitive and inconvenient. The oral administration route is also complicated because of complications associated with gastrointestinal irritation, drug metabolism in the liver and is often impractical if a patient is vomiting or nauseous. For many medications it is important that the administration regime is as simple and non-invasive as possible in order to maintain a high level of compliance by a patient. Aceclofenac is rapidly and completely absorbed after oral administration, peak plasma concentrations are reached 1 to 3 hours after an oral dose. But the drug is highly protein bound (7.99%). The presence of food does alter the extent of absorption of Aceclofenac and the absorption rate is reduced. So the administration of physiologically active agents, such as Aceclofenac, through the skin (‘transdermal drug delivery’) has received increased attention because it not only provides a relatively simple dosage regime but it also provides a relatively slow and controlled route for release of a physiologically active agent into the systemic circulation. However, transdermal drug delivery is complicated by the fact that the skin behaves as a natural barrier and therefore transport of agents through the skin is a complex mechanism. The objective of the study was to Design & Development of Aceclofenac Transdermal Patch, Physiochemical studies of the developed patch, selecting chemical enhancer for improving the transdermal permeation of poorly absorbed drugs, Evaluating of the release kinetics of the drugs.

EXPERIMENTAL

MATERIALS

Aceclofenac (Shanghai Shenxing Pharmaceutical Factory, China), polyvinyl alcohol (PVA; Hydrolysis-98%; Ash-1%, BDH Chemicals Ltd, Poole, England), Ethylcellulose (EC; Colorcon Asia Pvt. Limited, India), Di-n-butylphthalate (Assay ≥ 98%; Density: 1.042-1.045; Refractive index: 1.492-1.494; Acidity: ≤ 0.1 ml N%; Merck Ltd, Mumbai), Chloroform (CHCl3 = 119.38 g/mol; Purity: 99-99.4% VWR International Ltd, England), Nicotinamide (Potency: 99.511%; DSM Nutritional Product, USA), Polyvinylpyrrolidone (PVP; BASF). All the chemicals were used as received without any further purification.

Development of Aceclofenac Transdermal Patch

Matrix – type transdermal patches containing Aceclofenac were prepared using the different ratios of PVP and EC by solvent evaporation technique in cylindrical both sides open glass molds. The bottom of the mold was wrapped with aluminum foil on which the backing membrane was cast by pouring 4% w/v PVA solution followed by drying at 60°C for 6 h. The two polymers were weighted in requisite ratio and they were then dissolved in chloroform. di-n-butylphthalate 50% w/w of polymer composition was used as a plasticizer. The drug was added to the 40% w/w of the total weight of polymers, in the
homogeneous dispersion, by slow stirring with a mechanical stirrer. The uniform dispersion (2ml each) was cast on the PVA backing membrane cast earlier and dried at 40°C for 6h. The backing membrane was then glued to a gummy tape keeping matrix side upward. The wax papers were used to give a protective covering. This was the final shape of the formulation. The dry patches were kept in desiccators until use [5].

**Table 1: Composition of Prepared Patch**

<table>
<thead>
<tr>
<th>No.</th>
<th>Formulation Code</th>
<th>Ratio of PVP &amp; EC (mg)</th>
<th>Total weight of PVP &amp; EC</th>
<th>Chloroform (ml)</th>
<th>Di-n-Butyl Phthalate</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ACC1</td>
<td>1:3</td>
<td>500</td>
<td>5</td>
<td>50% w/w of polymer</td>
<td>40% w/w of polymer</td>
</tr>
<tr>
<td>2</td>
<td>ACC 2</td>
<td>2:2</td>
<td>500</td>
<td>5</td>
<td>50% w/w of polymer</td>
<td>40% w/w of polymer</td>
</tr>
<tr>
<td>3</td>
<td>ACC 3</td>
<td>3:5</td>
<td>500</td>
<td>5</td>
<td>50% w/w of polymer</td>
<td>40% w/w of polymer</td>
</tr>
</tbody>
</table>

**Drug-Excipient interaction study**

Drug-Excipient interaction study was performed using silica gel-coated TLC (Thin Layer Chromatography) plates and a mixture of one volume of hydrochloric acid, one volume of water six volume of glacial acetic acid and 11 volume of ethylacetate as mobile phase [6]. The TLC plates were prepared using slurry of silica-G. The prepared plates are activated at 110°C for 1.5 h. On the activated plates, 2 microliter of each solution in methanol containing (a) 12 mg/ml Aceclofenac containing different ratio of excipients, that is PVP, EC, Di-n-butyl phthalate were applied. The plates were dried in a stream of warm air for 10 minutes and then sprayed with ninhydrin solution. The plates were heated at 110°C for 15 min. The Rf values were calculated from the chromatogram obtained [7].

**Physical characteristics of the prepared films**

**Moisture Content**

The prepared films were weighted and individually and kept in a desiccator containing activated silica at room temperature for 24 h. The films were weighted again individually until it showed a constant weight. The percentage of moisture content was calculated as a difference between initial and final weight with respect to final weight [7].

**Moisture Uptake**

A weighed film kept in desiccators at normal room temperature for 24 h was taken out and exposed to 84% relative humidity (saturated solution of potassium chloride) in desiccators until a constant weight for the film was obtained. The percentage of moisture uptake was calculated as the difference between final and initial weight with respect to initial weight [7].

**Flatness**

Longitudinal strips were cut out from each film, one from the center and two from either side. The length of each strip was measured and the variation in the length because of non-uniformity in flatness was measured by determining percent constriction, considering 0% constriction is equivalent to 100% flatness. [7]
Constriction (%) = \((\frac{l_1 - l_2}{l_2})\times 100\)

Where \(l_1\) = initial length of each strip and \(l_2\) = final length of each strip.

**In-vitro Release – Dissolution Studies**

The release – rate determinations is one of the most important studies to be conducted for all controlled-release delivery systems. The dissolution studies of patches are very crucial, because one needs to maintain the drug concentration on the surface of stratum corneum consistently and substantially greater than the drug concentration in the body, to achieve a constant rate of drug permeation [8].

The dissolution of patches was performed using USP Basket Type Dissolution Apparatus. The patches were placed in respective baskets with their drug matrix exposed to phosphate buffer, pH 7.4. All dissolution studies were performed at 32°C, at 50 rpm, with each dissolution jar carrying 900 ml of buffer. Samples were withdrawn at different time intervals and analyzed using a UV spectrophotometer at 273 nm against blank. Cumulative amounts of drug released was plotted against time for different formulations [8].

**RESULTS**

TLC studies were performed to assess any interaction between the drug and excipients. The data obtained suggested that there was no interaction between the drug and the excipients because the \(R_f\) values of both the drug and the drug–excipient solutions were nearly similar (Table 2).

**Table 2: Determination of Drug-Excipient Interaction using the TLC method**

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>PVP/EC</th>
<th>(R_f) Value</th>
<th>(R_f) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Drug</td>
<td>Drug-Excipient</td>
</tr>
<tr>
<td>ACC1</td>
<td>1:3</td>
<td>0.709</td>
<td>0.756</td>
</tr>
<tr>
<td>ACC2</td>
<td>2:2</td>
<td>0.793</td>
<td>0.793</td>
</tr>
<tr>
<td>ACC3</td>
<td>3:5</td>
<td>0.794</td>
<td>0.828</td>
</tr>
</tbody>
</table>

An attempt was made at this point to learn whether the media phosphate buffer, pH 7.4, was able to maintain sink conditions in dissolution studies. \(E_{%cm}\) was 317.512 obtained from the solubility studies. Thus, phosphate buffer was chosen as the dissolution media because sufficient amount of drug dissolved in it (4–5 times the drug incorporated in patch), which is necessary to maintain sink condition.

The physicochemical studies like moisture content, moisture uptake, flatness etc provide information regarding the stability of the formulations. The moisture content and moisture uptake (Figure 1, 2) varied to a small extent in all the formulations were placed in respective baskets with their drug matrix exposed to phosphate buffer, pH 7.4. All dissolution studies were performed at 32°C, at 50 rpm, with each dissolution jar carrying 900 ml of buffer. Samples were withdrawn at different time intervals and analyzed using a UV spectrophotometer at 273 nm against blank. Cumulative amounts of drug released was plotted against time for different formulations [8].

**RESULTS**

TLC studies were performed to assess any interaction between the drug and excipients. The data obtained suggested that there was no interaction between the drug and the excipients because the \(R_f\) values of both the drug and the drug–excipient solutions were nearly similar (Table 2). However, there was increased moisture content with an increase in hydrophilic polymers. The results of moisture uptake studies for different formulations were very unusual as it shows some negative values may be due to the presence of nicotinamide, which prevent the moisture uptake, and the effect was loss of weight. The results of the flatness study showed that some of the formulations had very little differences in the strip lengths before and after their cuts. It indicates almost very near to 100% flatness observed in the formulated patches. Thus, a very little amount of constriction was observed in the film of different formulations and it indicates smooth flat surface of the patches. A 100% flatness of all the formulations indicates (Table 4) no amount of constriction in formulated transdermal membrane strips. Dissolution studies are important for ensuring the sustained release performance and the reproducibility of rate and duration of drug release.

It was observed that as the concentration of hydrophilic polymer, PVP, increased in the formulations, the rate of dissolution increased subsequently and the best result found in the polymer ratio 3:5.
To study the drug content into the patches a 5-cm² film was cut into small pieces, put into a 100-mL buffer (pH 7.4), and shaken continuously for 24 hours. Then the whole solution was ultrasonicated for 15 minutes. After filtration, the drug was estimated spectrofluorometrically at an excitation wavelength of 240 nm and an emission wavelength of 340 nm. The preliminary studies indicated that there was no interference of polymers in the excitation and emission wavelengths of the drug.

Table 3: % Drug content in the prepared patches
Folding endurance was determined by repeatedly folding the film at the same place until it broke. The number of times the film could be folded at the same place without breaking was the folding endurance value. Folding endurance test results indicated that the patches would not break and would maintain their integrity with general skin folding when applied. The results of skin irritation tests of the Aceclofenac transdermal patches in comparison with formalin (0.8%) showed that the transdermal systems induced negligible erythema and edema, but formalin induced severe erythema and edema. Formalin induced high grade of irritation, indicated by ‘severe’ inflammation and edema besides showing discontinuity in epidermis, thin epidermis, ulceration and hyperplasia. The skin irritation test of the transdermal formulations ACC3 (PVP: EC: 3:5) with nicotinamide showed a skin irritation score (erythema and edema) of less than 2 (Table 5).

According to Draize et al, compounds producing scores of 2 or less are considered negative (no skin irritation). Hence, the developed transdermal formulations are free of skin irritation.

### Table 4: Data for % Flatness & Thickness (Cm) uniformity of the films

<table>
<thead>
<tr>
<th>Formulation Code</th>
<th>Polymer Ratio(PVP: EC)</th>
<th>% Flatness</th>
<th>Thickness (Cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACC1</td>
<td>1:3</td>
<td>100.00</td>
<td>0.00800</td>
</tr>
<tr>
<td>ACC2</td>
<td>2:2</td>
<td>99.99</td>
<td>0.00800</td>
</tr>
<tr>
<td>ACC3</td>
<td>3:5</td>
<td>99.87</td>
<td>0.00900</td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td>99.95333</td>
<td>0.00833</td>
</tr>
<tr>
<td>SD</td>
<td></td>
<td>0.052203</td>
<td>0.000549</td>
</tr>
</tbody>
</table>

### Table 5: Skin Irritation Scores Following Transdermal Patch Administration

<table>
<thead>
<tr>
<th>Rat No.</th>
<th>Control</th>
<th>ACC3 (with Nicotinamide)</th>
<th>Formalin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Erythema</td>
<td>Edema</td>
<td>Erythema</td>
</tr>
<tr>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Average</td>
<td>0</td>
<td>0</td>
<td>1.17 ±0.3073</td>
</tr>
</tbody>
</table>

Erythema scale: 0, none; 1, slight; 2, well defined; 3, moderate; and 4, scar formation. Edema scale: 0, none; 1, slight; 2, well defined; 3, moderate; and 4, severe.
DISCUSSION

In this study, it was desired to design a TDDS of Aceclofenac using a polymeric matrix film. This allows one to control the overall release of the drug via an appropriate choice of polymers [9] and their blends studied here, utilizing the different diffusion pathways created due to the blend of polymers to produce overall desired steady and sustained drug release. Cumulative amounts of drug (Aceclofenac) released per cm² from the different TDDS of varied ratio of PVP and EC showed variable release patterns (Fig 3, 4, 5). The process of drug release in most of the controlled/sustained release devices including transdermal patches is governed by diffusion [10]. When this matrix patch comes into contact with an in vitro study fluid, thermodynamically compatible with the polymer, the fluid is absorbed into the polymer matrix and this initiates polymer chain dissolution process in the matrix [11-12]. When the active agent (drug) is released from the matrix in such a way that the rate of release of the drug remains constant, the release kinetics of the drug are believed to follow a zero-order kinetics [13]. The release kinetics was studied to identify the best possible release mechanism of the drug. The percentage of Aceclofenac was plotted against time to get the zero order plots (Fig 3). In addition the percentage of release was plotted against Square Root of Time in Minutes to get higuchi plot (Fig 4). Again the log remaining was plotted against time to get the first order plot (Fig 5). The higuchi plot showed reasonably straight line with high correlation coefficient.

Moisture content was increased with the increment of hydrophilic polymer, PVP and it was highest at the ratio of 3:5. Moisture contents in the other formulations were found to be low. The results of moisture uptake studies for different formulations were very unusual as it shows some negative values may be due to the presence of nicotinamide, which prevent the moisture uptake, and the effect was loss of weight.

![Figure 3](image1.png)

**Figure 3:** In-vitro drug dissolution profiles from Aceclofenac containing different matrix films prepared by using different ratios of PVP & EC with nicotinamide at pH 7.4. Data shows mean ± SE (n = 3).

![Figure 4](image2.png)

**Figure 4:** Higuchi plot for release profiles of Aceclofenac containing different matrix films prepared by using different ratios of PVP & EC with...
nicotinamide at pH 7.4. Data shows mean ± SE (n = 3).

![Graph](image)

**Figure 5:** First order plot for release profiles of Aceclofenac containing different matrix films prepared by using different ratios of PVP & EC with nicotinamide at pH 7.4. Data shows mean ± SE (n = 3).

**CONCLUSION**

The moisture content in the formulations was related with ratio of PVP and EC. It was observed that as the concentration of hydrophilic polymer, PVP, increased in the formulations, the rate of dissolution increased subsequently and the best result found for polymer ratio 3:5. The release kinetics was also studied to identify the best possible release mechanism of the drug by different types of plot like Zero order plot, Higuchi plot, First order plot. From study of skin reaction it was also found that there was no significant reaction was developed during the contact of patch with dermis, only a slight erythema and edema were developed when contacted with skin for 24 hours. So no or little irritation was observed. Finally from the study it was found that Aceclofenac could be given as Transdermal Patch and further *In vivo* and *In vitro* investigations are required.

**REFERENCES**


